Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon
(1) Objectives: The burden of SARS-CoV-2 infection in people living with HIV (PLHIV) in Gabon is unknown. (2) Methods: We conducted a cross-sectional seroprevalence study of SARS-CoV-2 immunoglobulin (Ig) G/M antibodies in PLHIV in Libreville from April 2022 to April 2023 after the fourth wave of th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | COVID |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8112/5/1/3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588751806660608 |
|---|---|
| author | Samira Zoa-Assoumou Hervé M’boyis-Kandem Pelagie Saphou-Damon Davy Ulrich Leger Mouangala Guy-Francis Nzengui Marina Mbani-Okoumba Claudine Kombila-Koumavor Gael Mourembou Brama Ibrahim Angelique Ndjoyi-Mbiguino |
| author_facet | Samira Zoa-Assoumou Hervé M’boyis-Kandem Pelagie Saphou-Damon Davy Ulrich Leger Mouangala Guy-Francis Nzengui Marina Mbani-Okoumba Claudine Kombila-Koumavor Gael Mourembou Brama Ibrahim Angelique Ndjoyi-Mbiguino |
| author_sort | Samira Zoa-Assoumou |
| collection | DOAJ |
| description | (1) Objectives: The burden of SARS-CoV-2 infection in people living with HIV (PLHIV) in Gabon is unknown. (2) Methods: We conducted a cross-sectional seroprevalence study of SARS-CoV-2 immunoglobulin (Ig) G/M antibodies in PLHIV in Libreville from April 2022 to April 2023 after the fourth wave of the pandemic. We used the WANTAI SARS-CoV-2 Ab ELISA targeting the SARS-CoV-2 spike, receptor-binding domain. (3) Results: Among 480 samples tested, the seroprevalence of IgG antibodies to SARS-CoV-2 spike protein was 87.5% (95% confidence interval (CI) 77.7–97.3%). History of SARS-CoV-2 diagnosis, ART treatment, and TCD4 lymphocyte count were not found to be associated with the presence of antibodies against SARS-CoV-2 among the study participants. However, having a detectable viral load (<i>p</i> = 0.0001), being vaccinated (COVID-19 vaccine, <i>p</i> = 0.04), and a history of COVID-19 (<i>p</i> < 0.0001) symptoms were associated with a higher risk of having anti-SARS-CoV-2 antibodies. (4) Conclusions: By early 2023, PLHIV in Gabon had high rates of SARS-CoV-2 seropositivity. To our knowledge, this is the first study to determine the seroprevalence of SARS-CoV-2 antibodies in PLHIV in Gabon. This study provides further evidence of anti-SARS-CoV-2 seroconversion in the absence of any vaccination in a particular target population. The surveillance of diseases of global health concern in PLHIV is crucial to estimate population-level exposure and inform public health responses. |
| format | Article |
| id | doaj-art-2ae39b7fe63b405d86b698e483dbcb11 |
| institution | Kabale University |
| issn | 2673-8112 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | COVID |
| spelling | doaj-art-2ae39b7fe63b405d86b698e483dbcb112025-01-24T13:27:56ZengMDPI AGCOVID2673-81122024-12-0151310.3390/covid5010003Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, GabonSamira Zoa-Assoumou0Hervé M’boyis-Kandem1Pelagie Saphou-Damon2Davy Ulrich Leger Mouangala3Guy-Francis Nzengui4Marina Mbani-Okoumba5Claudine Kombila-Koumavor6Gael Mourembou7Brama Ibrahim8Angelique Ndjoyi-Mbiguino9Laboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonInstitut des Maladies Infectieuses Pr Daniel Gahouma, Libreville BP 1343, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, GabonDépartement de Biologie, Faculté des Sciences, Université des Sciences et Techniques de Masuku, Libreville 942, GabonLaboratoire de Reference IST/Sida, Département de Bactériologie-Virologie, Université des Sciences de la Santé (USS), Libreville BP 4009, Gabon(1) Objectives: The burden of SARS-CoV-2 infection in people living with HIV (PLHIV) in Gabon is unknown. (2) Methods: We conducted a cross-sectional seroprevalence study of SARS-CoV-2 immunoglobulin (Ig) G/M antibodies in PLHIV in Libreville from April 2022 to April 2023 after the fourth wave of the pandemic. We used the WANTAI SARS-CoV-2 Ab ELISA targeting the SARS-CoV-2 spike, receptor-binding domain. (3) Results: Among 480 samples tested, the seroprevalence of IgG antibodies to SARS-CoV-2 spike protein was 87.5% (95% confidence interval (CI) 77.7–97.3%). History of SARS-CoV-2 diagnosis, ART treatment, and TCD4 lymphocyte count were not found to be associated with the presence of antibodies against SARS-CoV-2 among the study participants. However, having a detectable viral load (<i>p</i> = 0.0001), being vaccinated (COVID-19 vaccine, <i>p</i> = 0.04), and a history of COVID-19 (<i>p</i> < 0.0001) symptoms were associated with a higher risk of having anti-SARS-CoV-2 antibodies. (4) Conclusions: By early 2023, PLHIV in Gabon had high rates of SARS-CoV-2 seropositivity. To our knowledge, this is the first study to determine the seroprevalence of SARS-CoV-2 antibodies in PLHIV in Gabon. This study provides further evidence of anti-SARS-CoV-2 seroconversion in the absence of any vaccination in a particular target population. The surveillance of diseases of global health concern in PLHIV is crucial to estimate population-level exposure and inform public health responses.https://www.mdpi.com/2673-8112/5/1/3seroprevalenceSARS-CoV-2 antibodiesPLHIVLibreville |
| spellingShingle | Samira Zoa-Assoumou Hervé M’boyis-Kandem Pelagie Saphou-Damon Davy Ulrich Leger Mouangala Guy-Francis Nzengui Marina Mbani-Okoumba Claudine Kombila-Koumavor Gael Mourembou Brama Ibrahim Angelique Ndjoyi-Mbiguino Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon COVID seroprevalence SARS-CoV-2 antibodies PLHIV Libreville |
| title | Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon |
| title_full | Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon |
| title_fullStr | Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon |
| title_full_unstemmed | Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon |
| title_short | Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon |
| title_sort | seroprevalence of sars cov 2 infection among people living with hiv in libreville gabon |
| topic | seroprevalence SARS-CoV-2 antibodies PLHIV Libreville |
| url | https://www.mdpi.com/2673-8112/5/1/3 |
| work_keys_str_mv | AT samirazoaassoumou seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT hervemboyiskandem seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT pelagiesaphoudamon seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT davyulrichlegermouangala seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT guyfrancisnzengui seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT marinambaniokoumba seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT claudinekombilakoumavor seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT gaelmourembou seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT bramaibrahim seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon AT angeliquendjoyimbiguino seroprevalenceofsarscov2infectionamongpeoplelivingwithhivinlibrevillegabon |